Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Stock Jumped Today

By Keith Speights - Updated Jan 20, 2021 at 2:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech announced the presentation of encouraging data for its experimental COVID-19 antibody therapy STI-2020.

What happened

Shares of Sorrento Therapeutics (SRNE -9.21%) were jumping 5.1% as of 3:13 p.m. EST on Wednesday after rising as much as 12.5% earlier in the day. The gain came following the company's announcement Tuesday evening of the presentation of new data for its STI-2020 COVID-19 antibody therapy with new variants of the novel coronavirus SARS-CoV-2. 

So what

Sorrento executive Robert Allen presented some data yesterday at PepTalk 2021 and will make another presentation on Thursday. The company stated that this new data showed evidence of sustained binding potency of its experimental STI-2020 antibody therapy with the B.1.1.7 variant of SARS-CoV-2 initially identified in the U.K. and the B.1.351 variant initially identified in South Africa.

Scientist looking through a microscope

Image source: Getty Images.

This is certainly good news for Sorrento. There have been concerns that antibody therapies might not be as effective in treating the new variants of the novel coronavirus that causes COVID-19.

It's still really early, though. Sorrento's data came from in vitro assays in pre-clinical trials. Clinical studies in humans will be needed to conclusively establish that STI-2020 is safe and effective in treating COVID-19 patients, including those infected with the newly discovered variants. 

Now what

Sorrento received a green light from the Food and Drug Administration in December to move forward with a phase 1 clinical study evaluating STI-2020. Positive results from this study would likely provide another solid catalyst for the biotech stock. The company also awaits an FDA decision on Emergency Use Authorization for its COVI-STIX rapid COVID-19 diagnostics test.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$2.07 (-9.21%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.